UNLABELLED: The authors conducted an 8-year prospective non-randomised study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for haematological malignancy. The authors examined prospectively 75 patients (40 male/35 female) aged 2-17 years (median 6.5 years) at the time of diagnosis. The cardioprotection was given to 53 patients (26 male/17 female) and the standard protocol was used in 22 patients (14 male/8 female). The prospective echocardiographic evaluation was done before and after the chemotherapy and every year during the follow-up period. Dynamic stress echocardiography (DSE) was assessed in the final year. The clinical cardiotoxicity was not diagnosed. Higher cumulative doses of anthracycline were given in the dexrazoxane group (234+/-58 mg/m(2), median 240 mg/m(2) versus 203+/-86 mg/m(2), median 210 mg/m(2), P <0.04) and a significantly higher percentage of patients received cumulative doses >240 mg/m(2) of anthracycline ( P <0.05). During the follow-up period, the fractional shortening (FS) declined in the no-dexrazoxane group only in the 8th year and was significantly lower compared to the dexrazoxane group ( P <0.05). The pathological decrease in FS was present in 24% of patients; 41% in the no-dexrazoxane and 17% in the dexrazoxane groups, respectively ( P <0.05). DSE demonstrated lower rest EF and cardiac index (CI) in the no-dexrazoxane group ( P <0.05); however, neither the response of EF and CI to the stress echocardiography nor the exercise tolerance significantly differed between sub-groups. A higher number of patients in the dexrazoxane group had very good exercise tolerance (ET) >3 Watts/kg ( P <0.05) and a lower number responded with a decreased ET <2 Watts/kg ( P <0.05) compared to the no-dexrazoxane group. CONCLUSION: Dexrazoxane seems to reduce the risk of late subclinical cardiotoxicity. Dexrazoxane-treated patients revealed better exercise tolerance; however the haemodynamic response to the stress was no different in both sub-groups.

Department of Cardiology University Hospital Brno Jihlavska 20 62500 Brno Czech Republic

Zobrazit více v PubMed

N Engl J Med. 2004 Jul 8;351(2):145-53 PubMed

Lancet. 1991 Apr 6;337(8745):816-8 PubMed

Eur J Heart Fail. 2002 Jun;4(3):235-42 PubMed

Ann Intern Med. 1979 Nov;91(5):710-7 PubMed

Eur J Pediatr. 2001 Oct;160(10):607-10 PubMed

Pediatrics. 1992 May;89(5 Pt 1):942-9 PubMed

Cancer Treat Rev. 1991 Mar;18(1):1-19 PubMed

Pediatrics. 1994 Mar;93(3):433-7 PubMed

N Engl J Med. 2000 Apr 13;342(15):1077-84 PubMed

J Pediatr Hematol Oncol. 1996 Feb;18(1):72-5 PubMed

JAMA. 1991 Sep 25;266(12 ):1672-7 PubMed

J Clin Oncol. 2002 Mar 15;20(6):1677-82 PubMed

Prog Pediatr Cardiol. 2000 Nov 4;12(1):1-28 PubMed

Drugs. 1998 Sep;56(3):385-403 PubMed

Cancer Treat Rev. 1993 Jan;19(1):57-77 PubMed

Clin Cardiol. 2001 Oct;24(10):663-9 PubMed

N Engl J Med. 1991 Mar 21;324(12):808-15 PubMed

Cancer Treat Rep. 1978 Jun;62(6):873-9 PubMed

J Clin Oncol. 1996 Feb;14(2):362-72 PubMed

Curr Med Chem. 2001 Nov;8(13):1649-60 PubMed

J Clin Oncol. 2002 Jun 15;20(12):2895-903 PubMed

Ann Intern Med. 1996 Jul 1;125(1):47-58 PubMed

J Clin Oncol. 2004 Mar 1;22(5):769-73 PubMed

Arch Dis Child. 1996 Nov;75(5):416-22 PubMed

N Engl J Med. 1995 Jun 29;332(26):1738-43 PubMed

Med Pediatr Oncol. 1995 Jun;24(6):352-61 PubMed

Pediatr Hematol Oncol. 1997 May-Jun;14(3):213-22 PubMed

Curr Med Chem. 1998 Feb;5(1):1-28 PubMed

Br Heart J. 1993 Aug;70(2):185-8 PubMed

Med Pediatr Oncol. 1998 Dec;31(6):512-5 PubMed

Am Heart J. 1997 Feb;133(2):169-73 PubMed

Semin Oncol. 1998 Oct;25(5):525-37 PubMed

Cancer Prev Control. 1999 Apr;3(2):145-59 PubMed

Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection